Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseThrombocytopeniaSubgroupChemotherapy inducedICD10D69.6-MeSHThrombocytopeniaSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceEltrombopagRomiplostimSupportive substanceEltrombopagRomiplostimSupportive substanceEltrombopagRomiplostimSupportive substanceEltrombopagRomiplostimNo. Substances1Protocol classificationTherapy classificationother protocolIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksArthalgiaDiarrheaHeadacheIncrease AminotransferasesNauseaPruritusRashThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorSoff GWiner EDiseasegemcitabinbasierte Chemotherapie, solide Tumoren, ECOG <2Solide Tumoren, CIT > 4 Wochen, Grund für Verschiebung/Dosisreduktion, ECOG 0-2OriginDepartment of Medicine, Memorial Sloan–Kettering Cancer Center, New York, NY, USARhode Island Hospital, Providence, Rhode IslandProtocols in Revision 2 protocols foundProtocols under revision.Eltrombopag 100, Thrombocytopenia, Chemotherapy Induced (PID960 V1.0)Romiplostim 2, Thrombocytopenia, Chemotherapy Induced (PID961 V2.0)
